Connect Biopharma Holdings Ltd Dossier
Qualitative Analysis
Business overview
Connect Biopharma Holdings Limited (NASDAQ: CNTB) is a clinical-stage biopharmaceutical company dedicated to developing therapies for serious inflammatory diseases. The company's lead drug candidate is rademikibart (formerly CBP-201), a fully human monoclonal IgG4 antibody targeting interleukin-4 receptor alpha (IL-4Ŕ). Rademikibart blocks inflammatory signaling by both IL-4 and IL-13, which are key drivers of Type 2 helper T-cell (Th2) mediated inflammatory responses. Connect Biopharma is strategically positioning rademikibart to address significant unmet medical needs in respiratory and dermatological conditions, with a primary clinical focus on acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company operates out of San Diego, California, and has historically maintained research and development operations in Taicang, China.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Transitioning Connect Biopharma into a U.S.-centric clinical-stage biopharmaceutical company headquartered in San Diego, California, with a primary focus on advancing rademikibart for acute and chronic respiratory indications (asthma and COPD) in the U.S. and global markets.
Expected impact: Aims to capture first-mover advantage in the multi-billion dollar acute asthma and COPD exacerbation markets where no biologic therapies are currently approved.
Advancing the clinical development of rademikibart (an anti-IL-4Rα antibody) through the Phase 2 Seabreeze STAT global trials, evaluating its safety and efficacy as an adjunct to standard of care for acute exacerbations.
Expected impact: Establish clinical proof-of-concept for rapid onset of action and airway function improvement, enabling progression to pivotal Phase 3 trials.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Simcere holds exclusive rights to develop, manufacture, and commercialize rademikibart in Greater China (Mainland China, Hong Kong, Macau, and Taiwan). This partnership leverages Simcere's strong local regulatory and commercial execution, allowing Connect to focus resources on U.S. and global development.
Terms: Connect received a $24 million upfront payment and is eligible to receive up to $110 million in remaining development, regulatory, and commercial milestones, plus tiered royalties up to low double-digit percentages on net sales in Greater China.